[引用][C] Flashback Foreword: Gefitinib in Non–Small-Cell Lung Cancer: The IDEAL 1 Trial

TE Stinchcombe - Journal of Clinical Oncology, 2023 - ascopubs.org
The study by Fukuoka et al 1 published in Journal of Clinical Oncology in 2003 was a
randomized phase II study which investigated two doses of gefitinib (250 mg daily and 500 …
相关文章

[引用][C] Flashback Foreword: Gefitinib in Non-Small-Cell Lung Cancer: The IDEAL 1 Trial.

TE Stinchcombe - Journal of Clinical Oncology: Official Journal of …, 2023 - europepmc.org
Flashback Foreword: Gefitinib in Non-Small-Cell Lung Cancer: The IDEAL 1 Trial. - Abstract -
Europe PMC Sign in | Create an account https://orcid.org Europe PMC Menu About Tools …

[引用][C] Flashback Foreword: Gefitinib in Non-Small-Cell Lung Cancer: The IDEAL 1 Trial

TE Stinchcombe - … of clinical oncology: official journal of …, 2023 - pubmed.ncbi.nlm.nih.gov